The Improved Detection of 2-Hydroxyglutarate In Gliomas at 7 T Using High-Bandwidth Adiabatic Refocusing Pulses
Uzay E Emir 1 , Sarah Larkin 2 , Nick de Pennington 2 , Natalie Voets 1 , Puneet Plaha 3 , Richard Stacey 3 , James Mccullagh 4 , Stuart Clare 1 , Peter Jezzard 1 , Christopher Schofield 4 , Olaf Ansorge 2 , and Tom Cadoux-Hudson 3
FMRIB Centre, University of Oxford, Oxford,
Oxfordshire, United Kingdom,
Department of Clinical Neurosciences, University of
Oxford, Oxford, Oxfordshire, United Kingdom,
of Neurosurgery, John Radcliffe Hospital, Oxford
University Hospitals NHS Trust, Oxford, Oxfordshire,
of Chemistry, University of Oxford, Oxford, Oxfordshire,
Mutations in IDH1 and IDH2 occur in up to 80% of a
variety of glioma sub-types and lead to the production
of MR detectable metabolite, 2-hydroxyglutarate (2-HG).
In this abstract, we report results from a new
acquisition protocol at 7T to detect 2-HG and the rest
of the brain chemical profile in mutant IDH1/2 glioma
patient with a higher sensitivity than has previously
been achieved at clinical field. The new method at 7T is
not only expected to increase diagnostic accuracy but
also shorten the duration of the scan.
This abstract and the presentation materials are available to members only;
a login is required.